Human Neonatal Rotavirus Vaccine (RV3-BB) Produces Vaccine Take Irrespective of Histo-Blood Group Antigen Status
Karen Boniface, Sean G Byars, Daniel Cowley, Carl D Kirkwood, Julie E Bines
Journal of Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2020
BACKGROUND: VP4 [P] genotype binding specificities of rotaviruses and differential expression of histo-blood group antigens (HBGAs) between populations may contribute to reduced efficacy against severe rotavirus disease. P-based rotavirus vaccines could broaden protection in such settings, particularly in Africa, where the Lewis-negative phenotype and P rotavirus strains are common. METHODS: The association between HBGA status and G3P rotavirus vaccine (RV3-BB) take was investigated in a phase 2A study of RV3-BB vaccine involving 46 individuals in Dunedin, New Zealand, during 2012-2014. FUT2 and FUT3 genotypes were determined from DNA extracted from stool specimens, and frequencies ..View full abstract
Awarded by Australian National Health and Medical Research Council
Awarded by New Zealand Health Research Council International Investment Opportunities Fund Trans-Tasman Clinical Trials Collaborative Initiative
This work was supported by the Australian National Health and Medical Research Council (project grant ID491239), the New Zealand Health Research Council International Investment Opportunities Fund Trans-Tasman Clinical Trials Collaborative Initiative (08_T02), and the Victorian Government's Operational Infrastructure Support Program.